The authors reply

New England Journal of Medicine

Volumn 360, Issue 12, 2009, Pages 1258-1259

  Massie, Barry M ^a   Carson, Peter E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN;

CLINICAL TRIAL; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HEART EJECTION FRACTION; HEART FAILURE; HIGH RISK POPULATION; HUMAN; LETTER; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 63049095934     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. [Errata, N Engl J Med 2000;342:748,1376.]
2. McMurray JJ, Carson PE, Komajda M, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008; 10:149-56.
3. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738-44.